Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Journal of Clinical and Translational Medicine
Nidia Nursafitri
Universitas Jember
Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Ventilator Associated Pneumonia (VAP) Antibiogram of Dr. Soebandi Hospital, Jember In 2019 Dini Agustina; Nidia Nursafitri; Arswendo Ika Murthy; Bagus Hermansyah
Journal of Clinical and Translational Medicine Vol. 1 No. 1 (2026): August
Publisher : PT Litera Integra Nusantara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.67580/medixis.v1i1.89

Abstract

Ventilator-Associated Pneumonia (VAP) is a type of nosocomial infection that occurs after 48-72 hours of endotracheal intubation with a high mortality rate and is most commonly seen in hospital ICUs The high mortality rate in VAP cases could, among other things, be caused by the emergence of multidrug resistant (MDR) species that may be caused by irrational use of antibiotics. The existence of an antibiogram is expected to solve the problem. This study aimed to form a VAP antibiogram of dr. Soebandi Hospital in Jember City, East Java, Indonesia, can be used to reference rational therapy.This research is a descriptive study using secondary data obtained from medical records. The data will be collected and analyzed in a univariate manner, and then the analysis results will be displayed in graphs and tables. The number of samples used was 37 medical record data that matched the criteria and obtained 39 isolates. Of the 39 isolates, 22 different types of bacteria were obtained. These bacteria come from 7 different families. In addition, of the 39 identified types of bacteria, 29 of them were Gram-negative bacteria (74%), the remaining 10 were Gram-positive bacteria (26%). The antibiotics with the most useful and have a sensitivity level of more than 50% in this study were amikacin (77%), piperacillin-tazobactam (65%), and cephalexin (54%). These three antibiotics are also available in the parenteral form be used as empirical therapy for VAP.
Co-Authors Arswendo Ika Murthy Bagus Hermansyah Dini Agustina